StreetInsider.com News Articles

Form SCHEDULE 13G/A COLLEGIUM PHARMACEUTICAL Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Thu, 08 Oct 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20261008/27167897.html

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Tue, 06 Oct 2026 08:00:00 -0400

STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, launched Start Talking ADHD, an online resource hub offering practical guides to people living with attention-deficit/hyperactivity disorder (ADHD), and the families who support them. The guides are designed to help patients and caregivers prepare for conversations with healthcare providers, school administrators, and the people in their support networks.

ADHD is a neurodevelopmental disorder characterized by patterns of inattention, hyperactivity and impulsivity, or

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Tue, 06 Oct 2026 08:00:00 -0400

ADHD is a neurodevelopmental disorder characterized by patterns of inattention, hyperactivity and impulsivity, or

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Tue, 06 Oct 2026 08:00:00 -0400

New resource hub builds on Collegium’s growing ADHD portfolio and commitment to supporting people and families beyond the clinical setting

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Tue, 06 Oct 2026 08:00:00 -0400

New resource hub builds on Collegium’s growing ADHD portfolio and commitment to supporting people and families beyond the clinical setting

Form 144 COLLEGIUM PHARMACEUTICAL Filed by: Dreyer Scott

Wed, 30 Sep 2026 15:52:00 -0400

si-local-file:///var/storage/secattach/20260930/27128483.html

Oppenheimer Starts Collegium Pharmaceutical (COLL) at Outperform

Wed, 23 Sep 2026 06:11:22 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Outperform rating and a price target of $50.00.

The analyst comments "We initiate coverage of Collegium Pharmaceutical with an Outperform rating and $50 PT. We believe the market continues to value COLL as a mature pain company despite its transition toward a scalable, self-funding CNS growth platform. Jornay PM and Azstarys provide exposure to two differentiated, patent-protected ADHD assets capable of driving above-market growth through the next decade, supported by a shared and increasingly efficient commercial infrastructure. Meanwhile, the pain portfolio continues to generate durable cash flow that

Oppenheimer Starts Collegium Pharmaceutical (COLL) at Outperform

Wed, 23 Sep 2026 06:11:22 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Outperform rating and a price target of $50.00.

Leerink Starts Collegium Pharmaceutical (COLL) at Outperform

Wed, 09 Sep 2026 06:21:09 -0400

Leerink analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Outperform rating and a price target of $45.00.

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $23.37 yesterday.

Truist Securities Assumes Collegium Pharmaceutical (COLL) at Buy

Wed, 09 Sep 2026 06:11:45 -0400

Truist Securities assumes coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Buy rating and a price target of $49.00.

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $23.37 yesterday.

Collegium to Participate in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:

Morgan Stanley 24th Annual Global Healthcare Conference
Fireside Chat Date and Time: Tuesday, September 15, 2026, at 4:05 p.m. ET
New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Presentation Date and Time: Wednesday, September 16, 2026, at 9:00 a.m. ET
New York, NY

Live webcasts of

Collegium to Participate in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

Morgan Stanley 24th Annual Global Healthcare Conference
Fireside Chat Date and Time: Tuesday, September 15, 2026, at 4:05 p.m. ET
New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Presentation Date and Time: Wednesday, September 16, 2026, at 9:00 a.m. ET
New York, NY

Live webcasts of

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Mon, 24 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26969005.html

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Mon, 24 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26969005.html

Barclays flags an "attractive entry point" in this pharma stock

Thu, 20 Aug 2026 15:00:00 -0400

Barclays reiterated an Overweight rating on a pharmaceutical name in a note this week, arguing the roughly 20% share decline since second-quarter results has gone too far.

Collegium Pharma (NASDAQ: COLL) (NASDAQ: COLL) is the stock in question.

"Pain-fueled volatility overdone: <$30 Represents an Attractive Entry Point," analyst Jenna Davidner wrote, adding that the guidance cut "drove elevated volatility, which we think is largely overdone."

The bank trimmed its price target to $48 from $56, reflecting lower revenue and adjusted EBITDA estimates driven mainly by pricing dynamics for Nucynta. Shares are currently priced at around $27.40, with the stock down around 4.6% on

Barclays flags an "attractive entry point" in this pharma stock

Thu, 20 Aug 2026 15:00:00 -0400

Barclays reiterated an Overweight rating on a pharmaceutical name in a note this week, arguing the roughly 20% share decline since second-quarter results has gone too far.

Collegium Pharma (NASDAQ: COLL) (NASDAQ: COLL) is the stock in question.

Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays

Wed, 19 Aug 2026 03:21:13 -0400

Barclays analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $48.00 (from $56.00) while maintaining a Overweight rating.

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: FULLER & THALER ASSET MANAGEMENT, INC.

Fri, 14 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26932923.html

Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: FULLER & THALER ASSET MANAGEMENT, INC.

Fri, 14 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26932923.html

Collegium Pharma (COLL) 2700 contracts of August 39 calls trade

Thu, 13 Aug 2026 15:57:44 -0400

Collegium Pharma (NASDAQ: COLL) 30-day option implied volatility is at 49; compared to its 52-week of 33 to 76 with a focus on 2700 contracts of August 39 calls.

Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 12

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916506.html

Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 12

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916506.html

Collegium Pharmaceutical launches $50M accelerated share repurchase

Thu, 13 Aug 2026 07:30:37 -0400

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has entered into an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock, according to a company statement.

The ASR is part of a $150 million share repurchase program authorized by Collegium's board of directors in July 2025. Upon completion of the ASR, the company will have $100 million remaining under that program.

Under the terms of the agreement, Collegium will pay $50 million to Jefferies LLC and will receive an initial delivery of 1,556,420 shares, based on the $25.70 closing stock price of Collegium's common stock on August 12,

Collegium Announces $50 Million Accelerated Share Repurchase Program

Thu, 13 Aug 2026 07:30:00 -0400

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.

“Collegium’s

Collegium Announces $50 Million Accelerated Share Repurchase Program

Thu, 13 Aug 2026 07:30:00 -0400

“Collegium’s